JP2006523627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523627A5 JP2006523627A5 JP2006504635A JP2006504635A JP2006523627A5 JP 2006523627 A5 JP2006523627 A5 JP 2006523627A5 JP 2006504635 A JP2006504635 A JP 2006504635A JP 2006504635 A JP2006504635 A JP 2006504635A JP 2006523627 A5 JP2006523627 A5 JP 2006523627A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- amino
- hydroxy
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy, nitro, cyano, amino, carboxy, tetrazolyl Chemical group 0.000 claims 99
- 125000000217 alkyl group Chemical group 0.000 claims 74
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 57
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 34
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 31
- 125000003386 piperidinyl group Chemical group 0.000 claims 25
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 16
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 13
- 125000001589 carboacyl group Chemical group 0.000 claims 13
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 12
- 150000008331 benzenesulfonamides Chemical class 0.000 claims 10
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 125000003831 tetrazolyl group Chemical group 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 4
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 125000001425 triazolyl group Chemical group 0.000 claims 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010037391 Pulmonary granuloma Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000008393 encapsulating agent Substances 0.000 claims 2
- 239000000796 flavoring agent Substances 0.000 claims 2
- 235000013355 food flavoring agent Nutrition 0.000 claims 2
- 235000003599 food sweetener Nutrition 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 claims 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000000375 suspending agent Substances 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 claims 1
- RJKTVYBEKJWZDB-UHFFFAOYSA-N 3-[(1-benzyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-5-yl)sulfonyl]-4-(3,5-dichlorophenoxy)benzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CC3N(CC=4C=CC=CC=4)CCC3C2)=C1 RJKTVYBEKJWZDB-UHFFFAOYSA-N 0.000 claims 1
- VMQJZPBSTOZASQ-UHFFFAOYSA-N 3-[2-(aminomethyl)piperazin-1-yl]sulfonyl-4-(3,5-dichlorophenoxy)benzonitrile;dihydrochloride Chemical compound Cl.Cl.NCC1CNCCN1S(=O)(=O)C1=CC(C#N)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 VMQJZPBSTOZASQ-UHFFFAOYSA-N 0.000 claims 1
- VYQYZDYFOXDCCP-NRFANRHFSA-N 4-(3,5-dichlorophenoxy)-3-[(2s)-2-(1h-indol-3-ylmethyl)piperazin-1-yl]sulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2[C@H](CNCC2)CC=2C3=CC=CC=C3NC=2)=C1 VYQYZDYFOXDCCP-NRFANRHFSA-N 0.000 claims 1
- ROIGTEXJDMGHGH-NRFANRHFSA-N 4-(3,5-dichlorophenoxy)-3-[(3s)-3-(1h-indol-3-ylmethyl)piperazin-1-yl]sulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2C[C@H](CC=3C4=CC=CC=C4NC=3)NCC2)=C1 ROIGTEXJDMGHGH-NRFANRHFSA-N 0.000 claims 1
- YWKMXGKEWFYICO-UHFFFAOYSA-N 4-(3,5-dichlorophenoxy)-3-[2-[(2,5-dioxopyrrolidin-1-yl)methyl]piperazin-1-yl]sulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2C(CNCC2)CN2C(CCC2=O)=O)=C1 YWKMXGKEWFYICO-UHFFFAOYSA-N 0.000 claims 1
- HTLCBJVYPKLOIX-UHFFFAOYSA-N 4-(3,5-dichlorophenoxy)-3-[3-(1,2,4-triazol-1-ylmethyl)piperazin-1-yl]sulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CC(CN3N=CN=C3)NCC2)=C1 HTLCBJVYPKLOIX-UHFFFAOYSA-N 0.000 claims 1
- KVWLVBNBARNZSA-UHFFFAOYSA-N 4-(3,5-dichlorophenoxy)-3-[3-(tetrazol-2-ylmethyl)piperazin-1-yl]sulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CC(CN3N=NC=N3)NCC2)=C1 KVWLVBNBARNZSA-UHFFFAOYSA-N 0.000 claims 1
- IQXPWEGYBXICGU-UHFFFAOYSA-N 4-(3,5-dichlorophenoxy)-3-[3-[(2,5-dioxopyrrolidin-1-yl)methyl]piperazin-1-yl]sulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CC(CN3C(CCC3=O)=O)NCC2)=C1 IQXPWEGYBXICGU-UHFFFAOYSA-N 0.000 claims 1
- NZMQPWWKJLZBCA-DEOSSOPVSA-N 4-(3,5-dichlorophenoxy)-3-[4-[(2s)-2-(2-hydroxypropan-2-yl)pyrrolidin-1-yl]piperidin-1-yl]sulfonylbenzonitrile Chemical compound CC(C)(O)[C@@H]1CCCN1C1CCN(S(=O)(=O)C=2C(=CC=C(C=2)C#N)OC=2C=C(Cl)C=C(Cl)C=2)CC1 NZMQPWWKJLZBCA-DEOSSOPVSA-N 0.000 claims 1
- PNRTUIONPSQWOQ-UHFFFAOYSA-N 4-(3,5-dichlorophenoxy)-3-piperidin-4-ylsulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)C2CCNCC2)=C1 PNRTUIONPSQWOQ-UHFFFAOYSA-N 0.000 claims 1
- PFIASXVVRVJYMQ-UHFFFAOYSA-N 5-cyano-2-(3,5-dichlorophenoxy)-n-[2-(dimethylamino)ethyl]-n-[2-(2,5-dioxopyrrolidin-1-yl)ethyl]benzenesulfonamide Chemical compound C=1C(C#N)=CC=C(OC=2C=C(Cl)C=C(Cl)C=2)C=1S(=O)(=O)N(CCN(C)C)CCN1C(=O)CCC1=O PFIASXVVRVJYMQ-UHFFFAOYSA-N 0.000 claims 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- WNUYFETUVKKCIW-UHFFFAOYSA-N methyl 1-[5-cyano-2-(3,5-dichlorophenoxy)phenyl]sulfonyl-1,4-diazepane-2-carboxylate Chemical compound COC(=O)C1CNCCCN1S(=O)(=O)C1=CC(C#N)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 WNUYFETUVKKCIW-UHFFFAOYSA-N 0.000 claims 1
- ZBWMCCIIGVXTQM-UHFFFAOYSA-N n-[[1-[5-cyano-2-(3,5-dichlorophenoxy)phenyl]sulfonyl-1,4-diazepan-2-yl]methyl]methanesulfonamide Chemical compound CS(=O)(=O)NCC1CNCCCN1S(=O)(=O)C1=CC(C#N)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 ZBWMCCIIGVXTQM-UHFFFAOYSA-N 0.000 claims 1
- SSEGODWNGXAKAD-UHFFFAOYSA-N n-[[1-[5-cyano-2-(3,5-dichlorophenoxy)phenyl]sulfonylpiperazin-2-yl]methyl]acetamide Chemical compound CC(=O)NCC1CNCCN1S(=O)(=O)C1=CC(C#N)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 SSEGODWNGXAKAD-UHFFFAOYSA-N 0.000 claims 1
- JECWZDJOPWXDPW-UHFFFAOYSA-N n-[[1-[5-cyano-2-(3,5-dichlorophenoxy)phenyl]sulfonylpiperazin-2-yl]methyl]methanesulfonamide Chemical compound CS(=O)(=O)NCC1CNCCN1S(=O)(=O)C1=CC(C#N)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 JECWZDJOPWXDPW-UHFFFAOYSA-N 0.000 claims 1
- APZHVXXHZIYJFQ-UHFFFAOYSA-N n-[[4-[5-cyano-2-(3,5-dichlorophenoxy)phenyl]sulfonylpiperazin-2-yl]methyl]acetamide Chemical compound C1CNC(CNC(=O)C)CN1S(=O)(=O)C1=CC(C#N)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 APZHVXXHZIYJFQ-UHFFFAOYSA-N 0.000 claims 1
- KUXSVYCUQHZQIX-UHFFFAOYSA-N n-[[4-[5-cyano-2-(3,5-dichlorophenoxy)phenyl]sulfonylpiperazin-2-yl]methyl]methanesulfonamide Chemical compound C1CNC(CNS(=O)(=O)C)CN1S(=O)(=O)C1=CC(C#N)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 KUXSVYCUQHZQIX-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03006293 | 2003-03-24 | ||
| EP03006293.9 | 2003-03-24 | ||
| PCT/EP2004/002496 WO2004084898A1 (en) | 2003-03-24 | 2004-03-11 | 2-phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006523627A JP2006523627A (ja) | 2006-10-19 |
| JP2006523627A5 true JP2006523627A5 (enExample) | 2007-07-12 |
| JP5208412B2 JP5208412B2 (ja) | 2013-06-12 |
Family
ID=33040909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504635A Expired - Fee Related JP5208412B2 (ja) | 2003-03-24 | 2004-03-11 | ベンゼンスルホンアミド誘導体 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7674797B2 (enExample) |
| EP (2) | EP1997495B1 (enExample) |
| JP (1) | JP5208412B2 (enExample) |
| KR (1) | KR101109296B1 (enExample) |
| CN (2) | CN102146053A (enExample) |
| AR (1) | AR043648A1 (enExample) |
| AT (1) | ATE413178T1 (enExample) |
| AU (2) | AU2004224807A1 (enExample) |
| BR (1) | BRPI0408682A (enExample) |
| CA (1) | CA2520225C (enExample) |
| CL (1) | CL2004000626A1 (enExample) |
| CY (1) | CY1108746T1 (enExample) |
| DE (1) | DE602004017588D1 (enExample) |
| DK (1) | DK1608374T5 (enExample) |
| ES (2) | ES2315647T3 (enExample) |
| GT (1) | GT200400049A (enExample) |
| HN (1) | HN2004000103A (enExample) |
| IL (2) | IL171069A (enExample) |
| MX (1) | MXPA05010055A (enExample) |
| MY (2) | MY149046A (enExample) |
| NO (1) | NO332932B1 (enExample) |
| NZ (1) | NZ542920A (enExample) |
| PE (1) | PE20050991A1 (enExample) |
| PL (1) | PL1608374T3 (enExample) |
| PT (1) | PT1608374E (enExample) |
| RU (1) | RU2380356C2 (enExample) |
| SI (1) | SI1608374T1 (enExample) |
| TW (1) | TWI342777B (enExample) |
| UY (1) | UY28239A1 (enExample) |
| WO (1) | WO2004084898A1 (enExample) |
| ZA (1) | ZA200507806B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5613937A (en) | 1993-02-22 | 1997-03-25 | Heartport, Inc. | Method of retracting heart tissue in closed-chest heart surgery using endo-scopic retraction |
| JP2003081937A (ja) * | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
| EP1997495B1 (en) * | 2003-03-24 | 2013-01-02 | Axikin Pharmaceuticals, Inc. | 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders |
| KR101020397B1 (ko) | 2005-08-12 | 2011-03-08 | 에프. 호프만-라 로슈 아게 | 플루오로 치환된 2-옥소 아제판 유도체 |
| KR20080046209A (ko) * | 2005-09-22 | 2008-05-26 | 사노피-아벤티스 | Ｃｃｒ3 수용체 리간드로서의 신규한 아미노-알킬-아미드 유도체 |
| HUP0500877A2 (en) * | 2005-09-22 | 2007-05-29 | Sanofi Aventis | Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates |
| HUP0500886A2 (en) * | 2005-09-23 | 2007-05-29 | Sanofi Aventis | Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use |
| KR101176697B1 (ko) | 2006-04-20 | 2012-08-23 | 에프. 호프만-라 로슈 아게 | 케모카인 수용체의 다이아제판 유도체 조절자 |
| HUP0800478A2 (en) | 2008-07-31 | 2010-03-01 | Sanofi Aventis | Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands |
| HRP20150355T1 (hr) | 2009-01-12 | 2015-06-19 | Pfizer Limited | Sulfonamidni derivati |
| TWI510469B (zh) * | 2009-04-22 | 2015-12-01 | Axikin Pharmaceuticals Inc | ２，５－雙取代芳基磺醯胺ｃｃｒ３拮抗劑 |
| AR078120A1 (es) * | 2009-04-22 | 2011-10-19 | Axikin Pharmaceuticals Inc | Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida y composiciones farmaceuticas |
| AU2010239341B2 (en) * | 2009-04-22 | 2015-07-02 | Axikin Pharmaceuticals, Inc. | Arylsulfonamide CCR3 antagonists |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
| WO2011094535A2 (en) * | 2010-01-28 | 2011-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers of aging for detection and treatment of disorders |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| DK2542542T3 (en) * | 2010-03-02 | 2015-07-20 | Axikin Pharmaceuticals Inc | ISOTOPIC ENRICHED ARYL SULPHONAMIDE CCR3 ANTAGONISTS |
| CA2793391A1 (en) * | 2010-03-17 | 2011-09-22 | Axikin Pharmaceuticals, Inc. | Arylsulfonamide ccr3 antagonists |
| GB201009603D0 (en) * | 2010-06-08 | 2010-07-21 | Cambridge Entpr Ltd | Anti-inflammatory agent |
| EP2590957B1 (en) | 2010-07-09 | 2014-11-12 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| EP2590972B1 (en) | 2010-07-09 | 2015-01-21 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| AU2011313906B2 (en) * | 2010-10-11 | 2015-08-13 | Axikin Pharmaceuticals, Inc. | Salts of arylsulfonamide CCR3 antagonists |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| US9156799B2 (en) | 2012-09-07 | 2015-10-13 | Axikin Pharmaceuticals, Inc. | Isotopically enriched arylsulfonamide CCR3 antagonists |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| KR102155857B1 (ko) | 2013-12-09 | 2020-09-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 노화 관련 질환들의 치료를 위한 방법 및 조성물 |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| AU2015284307A1 (en) | 2014-07-01 | 2017-02-02 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN105884674B (zh) * | 2015-01-05 | 2019-07-26 | 南开大学 | 色氨酸衍生物及制备方法和在防治植物病毒、杀菌、杀虫方面的应用 |
| EA201890020A1 (ru) | 2015-06-15 | 2018-05-31 | Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити | Способы и композиции для лечения ассоциированных со старением состояний |
| ES2900302T3 (es) | 2016-04-28 | 2022-03-16 | Alkahest Inc | Fracciones de plasma como terapia para el crecimiento y la progresión del tumor |
| EA039316B1 (ru) | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| WO2018187503A1 (en) | 2017-04-05 | 2018-10-11 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| US10357513B2 (en) | 2017-04-26 | 2019-07-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| BR112021006743A2 (pt) | 2018-10-26 | 2021-07-13 | Alkahest, Inc. | uso de plasma e frações plasmáticas para melhoria de dor, cicatrização de ferida e recuperação pós-operatória |
| CN114835687B (zh) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2275354A (en) * | 1937-11-29 | 1942-03-03 | May & Baker Ltd | Preparation of new therapeutically useful heterocyclic compounds |
| GB1368948A (en) * | 1970-11-11 | 1974-10-02 | Manuf Prod Pharma | Pyridine derivatives |
| US4233409A (en) * | 1979-07-05 | 1980-11-11 | Monsanto Company | Polymeric blend |
| WO1989005836A1 (en) | 1987-12-14 | 1989-06-29 | The Dow Chemical Company | Abs compositions having trimodal rubber particle distributions |
| US5041498A (en) * | 1990-01-02 | 1991-08-20 | The Dow Chemical Company | Trimodal ABS compositions having good gloss and reduced gloss sensitivity |
| DE4404749A1 (de) * | 1994-02-15 | 1995-08-17 | Bayer Ag | ABS-Polymer-Zusammensetzungen mit gleichmäßiger matter Oberfläche |
| DE19507749A1 (de) * | 1995-03-06 | 1996-09-12 | Bayer Ag | Thermoplastische Formmassen vom ABS-Typ |
| DE19518025A1 (de) * | 1995-05-17 | 1996-11-21 | Bayer Ag | Thermoplastische ABS-Formmassen |
| DE69626684T2 (de) | 1995-12-08 | 2004-04-29 | Agouron Pharmaceuticals, Inc., La Jolla | Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung |
| GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| DE19649249A1 (de) * | 1996-11-28 | 1998-06-04 | Bayer Ag | Verbesserte thermoplastische Formmassen vom ABS-Typ |
| AU8576098A (en) | 1997-07-25 | 1999-02-16 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| EP1076557A1 (en) | 1998-04-27 | 2001-02-21 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| US6022984A (en) * | 1998-07-27 | 2000-02-08 | Pfizer Inc. | Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors |
| ATE309205T1 (de) | 1999-01-13 | 2005-11-15 | Warner Lambert Co | Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren |
| AU5473800A (en) | 1999-06-11 | 2001-01-02 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| WO2000076514A1 (en) | 1999-06-11 | 2000-12-21 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| WO2001029000A2 (en) * | 1999-10-15 | 2001-04-26 | Du Pont Pharmaceuticals Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| EP1237849A1 (en) | 1999-11-05 | 2002-09-11 | University College London | Activators of soluble guanylate cyclase |
| DE10008419A1 (de) | 2000-02-23 | 2001-08-30 | Bayer Ag | Polymerzusammensetzungen mit verbesserter Eigenschaftskonstanz |
| DE10008420A1 (de) | 2000-02-23 | 2001-08-30 | Bayer Ag | Polymerzusammensetzungen mit verbesserter Eigenschaftskonstanz |
| GB0013060D0 (en) * | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| CA2413418A1 (en) * | 2000-06-21 | 2001-12-27 | Joseph B. Santella | Piperidine amides as modulators of chemokine receptor activity |
| JP2003081937A (ja) * | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
| DE10145773A1 (de) | 2001-09-17 | 2003-04-03 | Bayer Ag | ABS-Zusammensetzungen mit verbesserten Eigenschaftskombinationen |
| CN100567266C (zh) * | 2001-11-14 | 2009-12-09 | 先灵公司 | 类大麻苷受体配体 |
| ITMI20021058A1 (it) | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
| JP2004217654A (ja) * | 2002-12-27 | 2004-08-05 | Japan Tobacco Inc | 縮合ｎ含有へテロ環化合物及びその医薬用途 |
| EP1997495B1 (en) | 2003-03-24 | 2013-01-02 | Axikin Pharmaceuticals, Inc. | 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders |
| JP2011147872A (ja) | 2010-01-21 | 2011-08-04 | Kansai Kanaami Kk | 積層焼結フィルター |
| CA2793391A1 (en) | 2010-03-17 | 2011-09-22 | Axikin Pharmaceuticals, Inc. | Arylsulfonamide ccr3 antagonists |
-
2004
- 2004-03-11 EP EP08010543A patent/EP1997495B1/en not_active Expired - Lifetime
- 2004-03-11 RU RU2005132616/04A patent/RU2380356C2/ru not_active IP Right Cessation
- 2004-03-11 CA CA2520225A patent/CA2520225C/en not_active Expired - Fee Related
- 2004-03-11 CN CN2011100309647A patent/CN102146053A/zh active Pending
- 2004-03-11 NZ NZ542920A patent/NZ542920A/en not_active IP Right Cessation
- 2004-03-11 AU AU2004224807A patent/AU2004224807A1/en not_active Abandoned
- 2004-03-11 SI SI200430947T patent/SI1608374T1/sl unknown
- 2004-03-11 ZA ZA200507806A patent/ZA200507806B/xx unknown
- 2004-03-11 WO PCT/EP2004/002496 patent/WO2004084898A1/en not_active Ceased
- 2004-03-11 MX MXPA05010055A patent/MXPA05010055A/es active IP Right Grant
- 2004-03-11 JP JP2006504635A patent/JP5208412B2/ja not_active Expired - Fee Related
- 2004-03-11 ES ES04719389T patent/ES2315647T3/es not_active Expired - Lifetime
- 2004-03-11 PT PT04719389T patent/PT1608374E/pt unknown
- 2004-03-11 KR KR1020057017943A patent/KR101109296B1/ko not_active Expired - Fee Related
- 2004-03-11 AT AT04719389T patent/ATE413178T1/de active
- 2004-03-11 PL PL04719389T patent/PL1608374T3/pl unknown
- 2004-03-11 EP EP04719389A patent/EP1608374B9/en not_active Expired - Lifetime
- 2004-03-11 BR BRPI0408682-1A patent/BRPI0408682A/pt not_active IP Right Cessation
- 2004-03-11 DE DE602004017588T patent/DE602004017588D1/de not_active Expired - Lifetime
- 2004-03-11 CN CN2004800135855A patent/CN1802159B/zh not_active Expired - Fee Related
- 2004-03-11 ES ES08010543T patent/ES2401911T3/es not_active Expired - Lifetime
- 2004-03-11 DK DK04719389.1T patent/DK1608374T5/da active
- 2004-03-11 US US10/550,482 patent/US7674797B2/en not_active Expired - Fee Related
- 2004-03-18 AR ARP040100901A patent/AR043648A1/es active IP Right Grant
- 2004-03-22 MY MYPI20081829A patent/MY149046A/en unknown
- 2004-03-22 GT GT200400049A patent/GT200400049A/es unknown
- 2004-03-22 MY MYPI20041019A patent/MY138926A/en unknown
- 2004-03-23 PE PE2004000301A patent/PE20050991A1/es not_active Application Discontinuation
- 2004-03-23 UY UY28239A patent/UY28239A1/es not_active Application Discontinuation
- 2004-03-23 TW TW093107694A patent/TWI342777B/zh not_active IP Right Cessation
- 2004-03-24 CL CL200400626A patent/CL2004000626A1/es unknown
- 2004-03-24 HN HN2004000103A patent/HN2004000103A/es unknown
-
2005
- 2005-09-22 IL IL171069A patent/IL171069A/en active IP Right Grant
- 2005-10-21 NO NO20054878A patent/NO332932B1/no not_active IP Right Cessation
-
2009
- 2009-01-30 CY CY20091100112T patent/CY1108746T1/el unknown
- 2009-07-16 US US12/504,606 patent/US20090286771A1/en not_active Abandoned
- 2009-08-25 IL IL200580A patent/IL200580A/en not_active IP Right Cessation
-
2011
- 2011-05-27 AU AU2011202499A patent/AU2011202499B2/en not_active Ceased
-
2013
- 2013-08-26 US US14/010,354 patent/US9206186B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523627A5 (enExample) | ||
| RU2005132616A (ru) | Производные 2-фенокси и 2-фенилсульфонамида с ссr3 антагонистической активностью для лечения астмы и других воспалительных или иммунологических заболеваний | |
| RU2003129502A (ru) | Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний | |
| JP2005519024A5 (enExample) | ||
| RU2436776C2 (ru) | ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT | |
| JP2007513957A5 (enExample) | ||
| RU2006124518A (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
| US20050187262A1 (en) | Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use | |
| RU2009126624A (ru) | Производные 2-(пиперидин-4-ил)-4-фенокси-или фенилаинопиримидина в качестве ненуклеозидных ингибитров обратной транскриптазы | |
| JP2017523972A5 (enExample) | ||
| CA2258728A1 (en) | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase | |
| JP2004538259A5 (enExample) | ||
| JP2005513123A5 (enExample) | ||
| JP2016512825A5 (enExample) | ||
| JP2005500321A5 (enExample) | ||
| KR20050084271A (ko) | 아미노인다졸 유도체 및 키나제 억제제로서의 이의 용도 | |
| JPWO2002072145A1 (ja) | Ｅｐ１アンタゴニストを有効成分として含有するうつ病の治療剤 | |
| JP2006527708A5 (enExample) | ||
| CA2531068A1 (en) | Substituted arylthiourea derivatives useful as inhibitors of viral replication | |
| RU2007127644A (ru) | Производные 4-аминопиперидина | |
| RU2004118063A (ru) | Производное 4,4-дифтор-1,2,3,4-тетрагидро-5н-бензазепина, его соль и содержащая его фармацевтическая композиция | |
| JP2020506192A5 (enExample) | ||
| RU2221788C2 (ru) | Оксоциклические соединения мочевины, фармацевтическая композиция, способ лечения | |
| JP2009503103A (ja) | アリールピリジン及びその使用方法 | |
| RU2007127864A (ru) | Производные n-[(4, 5-дифенил-3-алкил-2-тиенил)метил]амина (амид, сульфонамид, карбамат и карбамид) в качестве антагонистов рецепторов св1 каннабиноидов |